Tab Application Banner
  • Users Online: 3578
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
REVIEW ARTICLE
Year : 2009  |  Volume : 4  |  Issue : 1  |  Page : 15-19

Remission in rheumatoid arthritis: Which definition to use in the clinic?


Clinical Immunology and Rheumatology Service, Department of Medicine, All India Institute of Medical Sciences, New Delhi, India

Correspondence Address:
Ashok Kumar
Clinical Immunology and Rheumatology Service, Department of Medicine, All India Institute of Medical Sciences, New Delhi
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

Remission is the goal of treatment of rheumatoid arthritis today. However, no satisfactory definition of remission is available. A number of definitions have been used, viz. ACR, FDA, DAS, SDAI, CDAI, Clin28 (and Clin42), RAPID3 and Physician Global Assessment. FDA's definition is the most stringent definition currently because it demands not only the fulfilment of ACR criteria but also evidence of radiographic arrest by Larsen or modified Sharp's index while off all antirheumatic therapy. While DAS and its modifications require a computer software or a programmed calcula- tor, CDAI avoids this requirement altogether. A serious drawback of all current definitions is the presence of residual disease activity in a significant proportion of patients meeting the criteria of "remission". It appears that most defini- tions of remission identify a state of minimal disease activity (MDA)-a concept initially proposed by an OMERACT committee. Recently, it has been shown that a large proportion of patients deemed to be in clinical remission have evidence of active, ongoing disease process as revealed by MRI or ultrasound-power doppler studies. Perhaps, the best approach would be to aim at achieving a state of MDA first and then performing imaging studies to look for evi- dence of subclinical disease activity. If necessary, treatment should be escalated so that silent damage is prevented and deformities averted.


[PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed290    
    Printed16    
    Emailed0    
    PDF Downloaded49    
    Comments [Add]    

Recommend this journal